Recruitment for ongoing PAES/PASS/DUS and other non-interventional studies.

 

ONGOING STUDIES

  • „Depression and anxiety disorders in patients with incontinence - prevalence, knowledge and behavior of doctors and patients knowledge.”
  • „Medical treatment decisions and the factors affecting them to patients diagnosed with urinary incontinence and knowledge of patients attending urology clinic about urinary incontinence and its treatment.”
  • „Impact assessment of monotherapy and polytherapy of chronic prostatitis on the occurrence of erectile dysfunction and behavior analysis of therapy doctors to patients diagnosed with chronic prostatitis and patients' knowledge about the disease.”
  • „Psychiatrists treatment decisions taken to patients with newly diagnosed depression or schizophrenia, and the factors affecting them and the expectations of patients regarding the treatment administered.”
  • „Treatment decisions of physicians initiating treatment of cancer pain and the knowledge of patients about the possibility and efficacy of this pain.”
  • „Safety profile of high doses of quetiapine product Kwetaplex® in the Polish population.”
  • „Factors influencing the use of the preparation of quetiapine in classic and extended release the form in the treatment of schizophrenia and bipolar disorder (BD) and produced therapeutic effects in the population of Polish patients with these diseases.”
  • „Factors affecting change from used neuroleptic second generation on another formulation of the therapeutic class in the treatment of schizophrenia and produced as a result of this modification therapeutic effects Polish population of schizophrenic patients.”
  • „Quality of life in patients with schizophrenia treated with antipsychotics derivatives diazepines, oxazepines and thiazepines.”
  • „Safety profile of various doses and formulations of the levetiracetam product VETIRA® in the Polish population.”
  • „Safety profile of oral contraceptives KONTRACEPT®, OVULAN®, OVULASTAN® I OVULASTAN FORTE® in the population of Polish patients.”
  • „Factors affecting monotherapy and polytherapy in preparations containing one or two active substances in the treatment of open-angle glaucoma and ocular hypertension, and the quality of life and patient adherence to medical recommendations (compliance) depending upon the therapeutic regimen.”
  • „Factors influencing the preference in the use of therapeutic drugs that can block the activity of the RAAS (renin-angiotensin-aldosterone system) by primary care physicians, cardiologists and neurologists in the population of Polish patients.”
  • „Psychiatrists treatment decisions taken to patients with a diagnosis of depression with co-morbid insomnia and the factors affecting them, and the impact of the treatment for insomnia, sleep quality and daytime sleepiness observed in a population of patients.”
  • „Treatment decisions made by doctors to patients with symptoms of overactive bladder, depending on the primary cause of those disorders.”
  • „Assessment of patient awareness regarding the prevention of lower urinary tract disorders.”
  • „Education and assessment of patient awareness regarding the prevention of cardio - vascular diseases.”
  • „Urinary-tract disorders benign prostatic hyperplasia (BPH) diagnosis and treatment.”
  • „Use of the preparation Lactoangin® in the treatment of inflammation of the throat in children.”
  • „Evaluation quality of life of cancer patients taking intravenous bisphosphonates.”
  • „Therapeutic preferences and regimens most often used by primary care physicians in the pharmacotherapy of patients with a diagnosis of asthma or COPD.”
  • „Therapeutic preferences of medical specialists and their most frequently used therapeutic regimens in patients with a diagnosis of asthma or COPD.”
  • „Patient preference in choosing the drug's equivalent in generally accessible pharmacy.”
  • „The impact assessment of the medicinal product NOCLAUD® at the maximum distance of walking without pain in patients with peripheral arterial disease stage II disease according to Fontaine.”

 

If you want access to our research, please register first. After receiving confirmation from Europharma you can log in to the system.

 

REGISTRATION TO THE RESEARCH SYSTEM